Add Yahoo as a preferred source to see more of our stories on Google. Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an ...
TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Aug 12 (Reuters) - Pfizer (PFE.N), opens new tab said on Tuesday its cancer drug Padcev, in combination with Merck's (MRK.N), opens new tab Keytruda, significantly improved survival rates in patients ...
TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...
While the method may sound unfamiliar, it has been clinically validated for decades and remains central to preventing ...
A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results